Chargement en cours...
H19-Promoter-Targeted Therapy Combined with Gemcitabine in the Treatment of Pancreatic Cancer
Pancreatic cancer is the eighth cancer leading cause of cancer-related death in the world and has a 5-year survival rate of 1–4% only. Gemcitabine is a first line agent for advanced pancreatic therapy; however, its efficacy is limited by its poor intracellular metabolism and chemoresistance. Studies...
Enregistré dans:
| Auteurs principaux: | , , , , , , , , |
|---|---|
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
International Scholarly Research Network
2012
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3371723/ https://ncbi.nlm.nih.gov/pubmed/22701803 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5402/2012/351750 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|